Talus Bioscience has raised $11.2 million in new venture funding from a Seed+ round. The funding round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. The money will be invested to advance Talus Bio’s therapeutic programmes, which include Brachyury-driven cancers and an […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!